ClinicalTrials.gg

Program

HRS-7450

A development code. Also written as “HRS-7450 Injection”.

Its studies are mostly in Ischemic Stroke, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Nov 14, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine20 open or runningphase 2since Nov 14, 2025Jun 3, 2024none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-7450, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2024First study: phase 1 study in Ischemic StrokeFirst studyNCT06447415 · 64 enrolled · China
  2. Nov 14, 2025Phase 2 study in Ischemic StrokeNCT07233070 · 210 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07233070Ischemic Stroke · China2CompletedSep 17, 2026210
NCT06447415Ischemic Stroke · China1CompletedMar 18, 202564

How it is read

Names in the registry

  • “HRS-7450 Injection”, 3 entries
  • “HRS-7450”, 1 entry

Codes read as this program: HRS7450.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.